Maternal cardiac effect of Hydroxyethyl Starch (HES) using LiDCO in cesarean section
Maternal cardiac effect of hydroxyethyl starch(HES) solution at different time using the LiDCO rapid system in cesarean section
Guang Han
60 participants
May 7, 2014
Interventional
Conditions
Summary
This study evaluated the maternal cardiac effect of hydroxyethyl starch(HES) solution when administrated preload or afterload in cesarean section under spinal anesthesia through minimally invasive arterial monitoring system LiDCO rapid. Sixty patients undergoing selective cesarean section, aged 20 to 30 years old, were randomly divided into pre-loading HES group (group P) and after-loading HES group (group A). Except a routine BP, ECG, SpO2 monitoring, every patient was connected to the LiDCO rapid (arterial pressure waveform analysis) to monitor CO. After establishing venous access, group P and group A were respectively administered a rapid intravenous infusion of 6% hydroxyethyl starch solution HES 130/0.4 250ml before or after spinal anesthesia within 5 min. The LiDCO monitoring system could record the indexes of heart rate (HR), cardiac output (CO), mean arterial pressure (MAP) and left ventricle stroke volume (SV) continuously. We compared these values at some time points and incidence of hypotension. Results Group P was significantly higher than group A in MAP,CO and SV at these time points including T1, T2 and T3 after spinal anesthesia (P<0.05). But it had not statistical difference in MAP, CO and SV at other points (P>0.05). There were no significant differences in HR between the two groups at all points(P>0.05). Phenylephrine requirements in group P were lower than group A(P<0.05). Conclusions Administering HES before spinal anesthesia could increase the CO, MAP, SV and prevent hypotension more effectively. So pre-loading fluid therapy might have more stable cardiac effect in cesarean section with spinal anesthesia.
Eligibility
Inclusion Criteria1
- (1) primiparas who underwent elective cesarean section (2)age of 20–30 years, (3) body weight of 60–90 kg, (4) ASA class 1–2, (5) no contraindications to spinal anesthesia.
Exclusion Criteria1
- (1) multiple pregnancy, (2) height less than 150 cm, (3) placenta previa, (4) complications including diabetes mellitus, hypertensive diseases in pregnancy, etc. (5) contraindication to central neural blockade (patients refusal, raised intracranial pressure, hypovolemic states, abnormal coagulopathy).
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
A rapid intravenous infusion of 6% hydroxyethyl starch solution HES 130/0.4 250ml was administered immediately before and the other after spinal anesthesia. Group P is the intervention group, who received HES 250ml immediately prior to spinal anaesthesia. Group A is the control group, who received HES 250ml immediately following spinal anaesthesia. Dose administered and logged by anaesthetist.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12616000252415